Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results

Key Points

• Ligand exceeded second-quarter expectations, reporting adjusted EPS of $2.37 versus the $1.97 consensus and revenue of $63.69 million versus $61.30 million. Revenue increased 33.8% year over year.
• The company raised the low end of its fiscal 2026 adjusted EPS guidance to $9.00 while maintaining the $9.50 upper end, and reaffirmed royalty revenue guidance of $225 million to $250 million.
• The XOMA Royalty acquisition adds more than 120 assets and is expected to contribute approximately $0.50 in adjusted EPS during the second half of 2026 and $1.50 in 2027; however, the volixibat program faces a delay after the FDA recommended a Phase III trial.

Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported $2.37 EPS for the quarter, topping the consensus estimate of $1.97 by $0.40, FiscalAI reports. The company had revenue of $63.69 million during the quarter, compared to analyst estimates of $61.30 million. Ligand Pharmaceuticals had a return on equity of 20.06% and a net margin of 67.88%.The firm's revenue was up 33.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.60 earnings per share. Ligand Pharmaceuticals updated its FY 2026 guidance to 9.000-9.500 EPS.

Here are the key takeaways from Ligand Pharmaceuticals' conference call:

• Second-quarter results exceeded growth expectations, with total revenue up 34% year over year to $64 million, royalty revenue up 32% to $48 million, and adjusted diluted EPS up 48% to $2.37.
• The recently closed XOMA Royalty acquisition adds more than 120 assets, including seven commercial programs and approximately 14 late-stage clinical programs, and is expected to contribute about $0.50 of adjusted EPS in the second half of 2026 and $1.50 in 2027.
• Ligand raised the low end of 2026 adjusted EPS guidance to $9.00 while maintaining the $9.50 upper end, reaffirmed royalty revenue guidance of $225 million-$250 million, and retains approximately $700 million of deployable capital plus expected operating cash flow exceeding $200 million in 2026.
• Management highlighted a catalyst-rich 18-month period, including up to seven pivotal readouts and potential approvals or label expansions for products such as QTORIN rapamycin, OJEMDA, volixibat, and VABYSMO, while acknowledging the inherent binary risk of clinical development.
• Mirum’s volixibat program in primary sclerosing cholangitis faces a timeline delay after the FDA recommended a Phase III trial; Ligand said the company is pursuing further discussions and now targets a potential submission in the first half of 2027.

Ligand Pharmaceuticals Stock Down 2.3%

Ligand Pharmaceuticals stock traded down $6.99 during midday trading on Friday, hitting $293.15. 313,611 shares of the company were exchanged, compared to its average volume of 300,344. The company has a market cap of $5.87 billion, a PE ratio of 31.35, a price-to-earnings-growth ratio of 2.71 and a beta of 1.13. Ligand Pharmaceuticals has a fifty-two week low of $137.14 and a fifty-two week high of $326.63. The company's fifty day moving average price is $285.97 and its 200-day moving average price is $235.30. The company has a debt-to-equity ratio of 1.16, a current ratio of 34.52 and a quick ratio of 20.95.

Trending Headlines about Ligand Pharmaceuticals

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Ligand reported second-quarter adjusted EPS of $2.37, beating analysts’ $1.95 consensus estimate, while revenue of $63.69 million exceeded expectations of $60.87 million. Revenue increased 33.8% year over year, and EPS rose from $1.60 in the prior-year quarter. Ligand Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its fiscal 2026 adjusted EPS outlook to $9.00-$9.50, above the $8.13 analyst consensus. The outlook implies continued earnings growth and supports the investment case for Ligand’s royalty-focused business model. Ligand Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; 2026 Adjusted EPS Outlook Lifted, Revenue Outlook Reaffirmed
• Positive Sentiment: Royal Bank of Canada raised its price target from $340 to $345 and maintained an “outperform” rating. HC Wainwright also lifted its target from $289 to $358 and assigned a “buy” rating, signaling that analysts see further upside. Analyst Price Target Updates
• Neutral Sentiment: Ligand reaffirmed fiscal 2026 revenue guidance of $270 million-$310 million. Although the midpoint is below the $287.5 million consensus estimate, the range remains consistent with the company’s previous outlook and may reflect the timing of royalty and licensing revenue. Ligand Pharmaceuticals 2026 Q2 Results Presentation
• Negative Sentiment: The stock’s decline following the earnings beat suggests investors may have been looking for a larger revenue outlook increase or may be locking in gains after the shares’ strong run. The mixed revenue guidance could be limiting the immediate reaction to the otherwise favorable results. Biopharma Royalty Powerhouse Dips Despite Beat-and-Raise Quarter

Insider Buying and Selling

In other news, Director Stephen L. Sabba sold 2,145 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $254.00, for a total transaction of $544,830.00. Following the sale, the director owned 33,629 shares in the company, valued at $8,541,766. This trade represents a 6.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andrew Reardon sold 5,000 shares of the business's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $288.99, for a total transaction of $1,444,950.00. Following the transaction, the insider directly owned 41,514 shares in the company, valued at approximately $11,997,130.86. The trade was a 10.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 35,231 shares of company stock valued at $9,199,401 over the last three months. Company insiders own 5.60% of the company's stock.

Institutional Trading of Ligand Pharmaceuticals

Several large investors have recently modified their holdings of the business. Commonwealth Equity Services LLC bought a new stake in shares of Ligand Pharmaceuticals in the fourth quarter worth $209,000. Principal Securities Inc. boosted its stake in Ligand Pharmaceuticals by 237.4% during the 4th quarter. Principal Securities Inc. now owns 1,127 shares of the biotechnology company's stock valued at $213,000 after acquiring an additional 793 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Ligand Pharmaceuticals during the 3rd quarter valued at $210,000. Mackenzie Financial Corp acquired a new position in Ligand Pharmaceuticals during the 3rd quarter worth $207,000. Finally, Orion Porfolio Solutions LLC acquired a new position in Ligand Pharmaceuticals during the 3rd quarter worth $210,000. 91.28% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on LGND shares. HC Wainwright increased their target price on shares of Ligand Pharmaceuticals from $289.00 to $358.00 and gave the stock a "buy" rating in a research report on Thursday. Stifel Nicolaus boosted their price objective on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Royal Bank Of Canada increased their price objective on shares of Ligand Pharmaceuticals from $340.00 to $345.00 and gave the stock an "outperform" rating in a research report on Friday. Oppenheimer reissued an "outperform" rating and issued a $326.00 target price (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday, August 3rd. Finally, Bank of America lifted their target price on shares of Ligand Pharmaceuticals from $266.00 to $388.00 and gave the company a "buy" rating in a report on Thursday, July 9th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, Ligand Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $336.57.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company's product offerings center around several core platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source